Compare LGVN & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LGVN | SBFM |
|---|---|---|
| Founded | 2014 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.6M | 7.2M |
| IPO Year | 2021 | N/A |
| Metric | LGVN | SBFM |
|---|---|---|
| Price | $0.59 | $1.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $6.50 | ★ $7.00 |
| AVG Volume (30 Days) | ★ 436.6K | 60.1K |
| Earning Date | 11-04-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,437,000.00 | ★ $37,323,742.00 |
| Revenue This Year | N/A | $10.26 |
| Revenue Next Year | N/A | $32.63 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 13.24 |
| 52 Week Low | $0.53 | $1.17 |
| 52 Week High | $2.24 | $3.90 |
| Indicator | LGVN | SBFM |
|---|---|---|
| Relative Strength Index (RSI) | 40.15 | 40.46 |
| Support Level | $0.53 | $1.32 |
| Resistance Level | $0.65 | $1.48 |
| Average True Range (ATR) | 0.05 | 0.07 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 35.13 | 38.89 |
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.